Sarah Mazzilli, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Computational Biomedicine





Investigating the molecular events associated with the progression of premalignant squamous lung lesions for targeted chemoprevention.

Lung cancer kills more individuals in the United States annually than breast, colon and prostate cancers combined. Reduction of lung cancer mortality may be achieved by identification of those at the high risk of developing cancer, in addition to finding effective agents in which to intervene in the process. There has been limited success of candidate chemopreventive agents in lung cancer as most have selected based on work in pre-clinical models that do not adequately represent the precancerous and early stage lesions that are the focus in clinical chemoprevention trials for lung cancer. The interests of our laboratory involve developing models to aid in the understanding of the epithelial and immune modulations that are involved in the progression and regression of premalignant squamous lesions to frank lung squamous cell carcinoma with a particular focus on identifying and testing targeted agents on appropriate models that allow for translation to clinical intervention studies. To do this the our lab utilized novel single cell and multiplex imaging technologies to characterize the immune and epithelial alterations enabling lung carcinogenesis and study mechanisms to intercept this process. Our lab also works closely with members of the section of Computational Biomedicine as well as national and international collaborators on the Pre-Cancer Genome Atlas (PCGA) and the NCI- Human Tumor Atlas leading the effort to further understand the molecular underpinnings of lung cancer development to advance early detection and intervention.


Lung Pre-Cancer Atlas (PCA) Cohort Registry
01/01/2019 - 01/01/2023 (PI)
Johnson & Johnson


Developing in vitro systems of Jung squamous carcinoma for drug discovery
01/22/2018 - 01/21/2022 (PI)
Janssen Research & Development, LLC


Pre-Cancer Genome Atlas 2.0 (PCGA 2.0)
12/22/2017 - 12/21/2021 (PI)
Janssen Research & Development, LLC


Characterization a Mouse Model of Lung Squamous Premalignancy & Pre-Clinical Intervention Studies
12/22/2017 - 12/21/2020 (PI)
Janssen Research & Development, LLC





Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, Perdomo C, Schaffer M, Liu G, Zhang S, Liu H, Vick J, Dhillon SS, Platero SJ, Dubinett SM, Stevenson C, Reid ME, Lenburg ME, Spira AE. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun. 2019 04 23; 10(1):1856.View Related Profiles. PMID: 31015447.
     
  2. Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T. Commensal Microbiota Promote Lung Cancer Development via ?d T Cells. Cell. 2019 Feb 21; 176(5):998-1013.e16. PMID: 30712876.
     
  3. Beane J, Mazzilli SA, Tassinari AM, Liu G, Zhang X, Liu H, Buncio AD, Dhillon SS, Platero SJ, Lenburg ME, Reid ME, Lam S, Spira AE. Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression. Clin Cancer Res. 2017 Sep 01; 23(17):5091-5100.View Related Profiles. PMID: 28533227.
     
  4. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 01; 77(7):1510-1541.View Related Profiles. PMID: 28373404; DOI: 10.1158/0008-5472.CAN-16-2346;.
     
  5. Campbell JD, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, Spira AE. The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prev Res (Phila). 2016 Feb; 9(2):119-24.View Related Profiles. PMID: 26839336; DOI: 10.1158/1940-6207.CAPR-16-0024;.
     
  6. Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model. Cancer Prev Res (Phila). 2015 Oct; 8(10):895-904. PMID: 26276745; PMCID: PMC4664525; DOI: 10.1158/1940-6207.CAPR-14-0403;.
     
  7. McDowell GS, Gunsalus KT, MacKellar DC, Mazzilli SA, Pai VP, Goodwin PR, Walsh EM, Robinson-Mosher A, Bowman TA, Kraemer J, Erb ML, Schoenfeld E, Shokri L, Jackson JD, Islam A, Mattozzi MD, Krukenberg KA, Polka JK. Shaping the Future of Research: a perspective from junior scientists. F1000Res. 2014; 3:291. PMID: 25653845; DOI: 10.12688/f1000research.5878.1;.
     

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 7 publications over 5 distinct years, with a maximum of 2 publications in 2017 and 2019

YearPublications
20141
20151
20161
20172
20192
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Mazzilli's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department